DOCSLIB.ORG

Long-Term Results of Isotretinoin in the Treatment of 68 Patients with Hidradenitis Suppurativa

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Long-Term Results of Isotretinoin in the Treatment of 68 Patients with Hidradenitis Suppurativa Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa Jurr Boer, MD, PhD, and Mirjan J. P. van Gemert, MD Deventer, The Netherlands Background: Oral isotretinoin has been used to treat mild to severe hidradenitis suppura- tiva (HS). Objective: We reviewed the results of low-dose isotretinoin for 4 to 6 months in the treat- ment of 68 patients with HS. Methods: This is a retrospective study. Data are presented in terms of response rate, long- term follow-up, and the relation between response rate and severity. Results: In 16 patients (23.5%), the condition completely cleared during initial therapy and 11 patients (16.2%) maintained their improvement during the follow-up period. Treatment was more successful in the milder forms of HS. Conclusion: Monotherapy with isotretinoin for patients with HS usually has a limited ther- apeutic effect. (J Am Acad Dermatol 1999;40:73-6.) Hidradenitis suppurativa (HS) is a chronic PATIENTS AND METHODS inflammatory disorder, usually located in the axil- The details of the patients at the start of the study are lae and genitocrural areas. Histopathologic studies shown in Table II. In the last 10 years, 68 patients (59 suggest that HS is a disease of the follicles with women, 9 men) with long-standing HS were treated apocrine involvement as a secondary event,1-4 so with oral isotretinoin as monotherapy for 4 to 6 months, the term acne inversa has been suggested.3,4 In as used in the treatment of acne vulgaris.5,11 In women some patients antibiotic and corticosteroid therapy of child-bearing age, effective contraception without or surgical management can control the disease. antiandrogens such as cyproterone acetate was used Isotretinoin is an effective treatment for acne con- throughout the treatment period. The severity of HS was 12 globata, with good long-term results,5 but the graded clinically according to O’Loughlin et al as response in HS is less well established. A few mild, moderate, or severe. Twenty patients (Table III) did not complete the prescribed minimum course of 4 investigators have evaluated the effects of months’ treatment. They dropped out for a variety of isotretinoin on HS, with mixed results. These case reasons including side effects (3 of 20 patients), poor reports and the results of studies with small num- response (7 of 20), a combination of side effects and bers of patients are summarized in Table I.6-10 poor response (7 of 20), and loss of motivation (3 of In an initial report we described our results from 20). Table III summarizes the treatment data. Clinical administration of low-dose isotretinoin to 21 status was judged by both the patients and the physician patients with HS; patients were observed for up to according to Dicken, Powell, and Spear,7 and was 24 months.9 In the present study we enrolled 68 scored as no change, improvement, marked improve- patients, including the already mentioned 21 ment, or clear, and graded accordingly from 0 to +3. patients, and focused on the response rate, long- After the completion of treatment, patients were term follow-up, and the possibility of a relation reexamined up to 6 months later. After this, data on clin- between response rate and severity. ical status and subsequent treatment for HS were col- lected by physical examination, status surveys, or tele- phone interviews. In our long-term follow-up we could identify an improvement score of +3 (virtually clear), From the Department of Dermatology, Deventer Hospital. but the remaining scores (+2, +1, etc) could not be Reprint requests: J. Boer, MD, PhD, Department of Dermatology, scored reliably by the physician or the patient. Deventer Hospital, Postbox 5001, 7400 GC Deventer, The Netherlands. Six patients received an intralesional injection of Copyright © 1999 by the American Academy of Dermatology, Inc. corticosteroid once for an abscesslike swelling during 0190-9622/99/$8.00 + 0 16/1/93164 isotretinoin treatment and four after the treatment 73 Journal of the American Academy of Dermatology 74 Boer and van Gemert January 1999 Table I. Summary of previously published studies of isotretinoin therapy for hidradenitis suppurativa (HS) Duration of Duration Improvement No. of Dose treatment Follow-up of Severity score* Author(s) patients (mg/kg/d) (mo) (mo) HS (y) of HS (No. of patients) Jones, Cunliffe, 3 1.0 4 — 20-30 Severe 0 (3) and King6 (1982) Dicken, Powell, 8 0.71-1.2 4 2-6 5-35 Extensive +3 (1), +2 (3), +1 and Spear7 (1984) and active (1), 0 (2), –1 (1) Norris and 6 1.0 4 2 Many Severe 0 (6) Cunliffe8 (1986) years Boer9 (1988) 21 0.5-0.67 4-6 3-24 1-25 Mild to +3 (6), +2 (5), severe +1 (3), 0 (1), dropped out (6) Brown, Gallup, 1 1.0 4 4 3 Severe +3 (1) and Brown10 (1988) *Improvement score: +3 = clear, +2 = marked improvement, +1 = improvement, 0 = no change, –1 = worse. Table II. Patient and disease characteristics at Table III. Isotretinoin treatment of hidradenitis baseline suppurativa No. of patients 68 (F, 59; M, 9) No. of patients treated 68 Mean age and range (y) 32.6 (15-54) No. of patients who completed 48 Mean duration of HS and range (y) 4.8 (1-30) treatment No. of patients with HS alone 60 Mean daily dose of isotretinoin No. of patients with HS and acne 8 and range (mg/kg body weight) 0.56 (0.50-0.81) conglobata Mean duration of treatment and 5 (4-6) Affected areas (No. of patients) range (mo) Genitocrural 45 Mean duration of follow-up and 46 (6-107) Axillary 6 range (mo) Axillary and genitocrural 17 remaining 32 patients with a score of +2, +1, or 0 course. Patients who required any further therapy were at the end of treatment, an exact score at the end of rated as treatment failures. The chi-square test and the the follow-up period of this retrospective study Wilcoxon two-sample test were used to compare the was difficult to obtain and of no relevance, because outcomes for patients with initially different severity of all these patients were dissatisfied with their disease. response. At the end of the therapy with isotretinoin, none RESULTS of the patients with severe HS scored +3, compared In the present trial 68 patients were treated with with 16 patients with mild and moderate forms of isotretinoin, of whom 20 (29.4%) did not complete HS, a statistically significant difference (P < .01, the minimum initial 4 months of therapy. Table IV chi-square test). Furthermore, Table V indicates that shows that 16 (23.5%) of the 68 patients achieved patients with initially mild forms of HS were more a score of +3 (clear) at the end of treatment, 14 likely to achieve improvement scores of +2 and +3 (20.6%) of the 68 scored +2, 11 (16.2%) scored than were patients with moderate and severe forms; +1, and 7 (10.3%) scored 0. In 11 of the 16 respon- this difference was statistically significant (P < .05, ders with a score of +3 this response persisted Wilcoxon two-sample test). throughout the follow-up period (range, 6 to 107 months; mean, 57 months). The scores of the DISCUSSION remaining 5 patients decreased from +3 to +2 (3 The many different therapies used to treat HS patients), +1 (1 patient), or 0 (1 patient). For the indicate an absence of a standard and universally Journal of the American Academy of Dermatology Volume 40, Number 1 Boer and van Gemert 75 Table IV. Long-term response of HS to Table V. Responses to isotretinoin therapy in isotretinoin treatment (68 patients) patients with HS of different severities at base- No. of patients line Improvement score At the end At the end Mean duration Clinical grading of the severity of treatment of of follow-up of HS at baseline 0 +1 +2 +3 Response HS (4-6 mo) follow-up and range (mo) Mild 0 0 2 4 +3 16 (23.5%) 11 (16.2%) 57 (6-107) Moderate 5 6 2 12 +2 14 (20.6%) NR NR Severe 2 5 10 0 +1/0 18 (26.5%) NR NR Drop-outs 20 (29.4%) Improvement score: +3 = clear, +2 = marked improvement, +1 = improvement, 0 = no change. NR, No relevance. disease. Furthermore, these authors advocated sur- gical intervention as the treatment of choice. They recommended the use of oral isotretinoin because accepted therapy. Because isotretinoin is effective of its antiinflammatory activity during the weeks for acne it seems reasonable to suppose that or months before surgery and perhaps also postop- isotretinoin might also be effective in HS. However, eratively. We agree that surgical treatment is the our experience with low-dose isotretinoin as first choice for all intertriginous lesions. Until monotreatment in 68 patients over a period of recently, wide excisions, well beyond the clinical almost 9 years confirms our early impression and borders of activity were recommended. The disad- previous reports (Table I) that isotretinoin is only vantages of surgery are the often long hospitaliza- moderately effective in the management of HS. Our tion and not always cosmetically acceptable study lacks a control group treated with antibiotics results. However, there are other, relatively simple as a comparison, so no statement as to relative effi- surgical treatments with excellent results such as 13 cacy can be made. However, many patients in our the deroofing technique and CO2 excision, both study had not responded to oral antibiotics or with second-intention healing.14 surgery, or had relapsed after such treatment.
Load more

Recommended publications
  • Outpatient Acne Care Guideline
    Outpatient Acne Care Guideline Severity Mild Moderate Severe < 20 comedones or < 20-100 comedones or 15-50 > 5 cysts, >100 comedones, or inflammatory lesions inflammatory lesions >50 inflammatory lesions Initial Treatment Initial Treatment Initial Treatment Benzoyl Peroxide (BP) or Topical Combination Therapy Combination Therapy Topical Retinoid Retinoid + BP Oral antibiotic or OR + (Retinoid + Antibiotic) + BP Topical retinoid Topical Combination Therapy or + BP + Antibiotic Retinoid + (BP + Antibiotic) or OR BP Retinoid + BP Oral antibiotic + topical retinoid + +/- or BP Topical antibiotic Retinoid + Antibiotic + BP or Topical Dapsone IF Inadequate Response IF Inadequate Response IF Inadequate Consider dermatology Response referral Change topical retinoid Consider changing oral concentrations, type and/or antibiotic formulation AND or Add BP or retinoid, if not already Change topiocal combination Consider isotretinoin prescribed therapy Consider hormone therapy or and/or (females) Change topical retinoid Add or change oral antibiotic concentrations, type and/or or formulation Consider isotretinoin Additional Considerations or Consider hormone therapy (females) Change topical comination Previous treatment/history Side effects therapy Costs Psychosocial impact Vehicle selection Active scarring Ease of use Regimen complexity Approved Evidence Based Medicine Committee 1-18-17 Reassess the appropriateness of Care Guidelines as condition changes. This guideline is a tool to aid clinical decision making. It is not a standard of care. The physician should deviate from the guideline when clinical judgment so indicates. GOAL: Pediatricians should initiate treatment for cases of “Mild” to “Severe” acne (see algorithms attached). Pediatricians should also counsel patients in order to maximize adherence to acne treatment regimens: 1. Realistic expectations. Patients should be counseled that topical therapies typically take up to 6-8 weeks to start seeing results.
    [Show full text]
  • Long-Term Use of Spironolactone for Acne in Women: a Case Series of 403 Patients
    Long-term use of spironolactone for acne in women: A case series of 403 patients Vaibhav Garg, BS,a JulianaK.Choi,MD,PhD,b William D. James, MD,b and John S. Barbieri, MD, MBAb Philadelphia, Pennsylvania Background: There are limited data regarding the long-term outcomes of spironolactone use for women with acne and its effect on truncal acne. Objective: To comprehensively describe outcomes of patients treated with spironolactone in routine clinical practice, including long-term outcomes. Methods: We performed a retrospective case series of 403 adult women treated for acne with spironolactone at an academic medical center between 2008 and 2019. Rates of objective, as assessed by Comprehensive Acne Severity Scale scores, and subjective acne clearance were evaluated, as well as rates of treatment discontinuation, dosage changes, and drug survival. Logistic regression was used to assess for association between incidence of menstrual adverse effects and combined oral contraceptive use. Results: As evaluated by Comprehensive Acne Severity Scale scores, at the first follow-up, 75.5%, 84.0%, and 80.2% of patients with available data had reduction or complete clearance of acne on the face, chest, and back, respectively. The mean drug survival was 470.7 days. Menstrual adverse effects were less common among those using combined oral contraception (odds ratio, 0.23; 95% confidence interval, 0.11-0.50). Limitations: This study was conducted at a single academic medical center. Conclusions: Spironolactone improves clinical outcomes and is well tolerated for many adult women with acne using it for an extended duration. ( J Am Acad Dermatol 2021;84:1348-55.) Key words: acne; acne vulgaris; birth control pill; combined oral contraceptive; comprehensive acne severity scale; oral antibiotics; outcomes; spironolactone.
    [Show full text]
  • 1 EMA Tender EMA/2017/09/PE, Lot 2 Impact of EU Label
    EMA tender EMA/2017/09/PE, Lot 2 Impact of EU label changes and revised pregnancy prevention programme for oral retinoid containing medicinal products: risk awareness and adherence Protocol • Prof. Anna Birna Almarsdóttir, Professor in Social and Clinical Pharmacy at the Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen • Prof. Marcel Bouvy, Professor of Pharmaceutical Care at the Division of Pharmacoepidemiology & Clinical Pharmacology of the Department of Pharmaceutical Sciences, Utrecht University. • Dr Rob Heerdink, Associate Professor at the Division of Pharmacoepidemiology & Clinical Pharmacology of the Department of Pharmaceutical Sciences, Utrecht University. • Dr Teresa Leonardo Alves, Researcher at the Centre for Health Protection, National Institute for Public Health and the Environment, The Netherlands. 1 Table of contents Background ...................................................................................................................... 3 Aims of the study ............................................................................................................. 4 Methods ........................................................................................................................... 4 Setting ........................................................................................... Error! Bookmark not defined. Study design ............................................................................................................................ 4 Population
    [Show full text]
  • Isotretinoin (Accutane) and Pregnancy
    Isotretinoin (Accutane®) This sheet talks about exposure to isotretinoin in a pregnancy or while breastfeeding. This information should not take the place of medical care and advice from your healthcare provider. What is isotretinoin? Isotretinoin is a prescription medication taken by mouth to treat severe cystic acne that has not responded to other treatments. Isotretinoin is a form of Vitamin A. It has been sold under brand names such as Accutane®, Absorica®, Amnesteem®, Claravis®, Epuris®, Clarus®, Myorisan®, Sotret®, and Zenatane®. How long after a woman stops taking isotretinoin should she wait to become pregnant? How long does isotretinoin stay in the body? It is recommended that a woman wait one month after stopping isotretinoin before trying to become pregnant. Usually, isotretinoin is no longer found in a woman’s blood 4-5 days after the last dose and most of its by-products should be gone within 10 days after the last dose. However, the time it takes isotretinoin to be cleared from the body can be longer in some people, which is why it is recommended to wait at least one month after stopping isotretinoin before trying to become pregnant. Can isotretinoin make it more difficult to get pregnant? Women who are trying to become pregnant should not be taking isotretinoin. There have been reports of irregular menstrual periods in some women taking isotretinoin. There are no reports of problems getting pregnant while taking isotretinoin. I just found out I am pregnant. Should I stop taking isotretinoin? Stop taking the medication right away. As soon as possible, call the healthcare provider who prescribed the isotretinoin and the healthcare provider who will be taking care of you during your pregnancy.
    [Show full text]
  • Isotretinoin for Neuroblastoma
    Isotretinoin for Neuroblastoma Isotretinoin (EYE so TRET in oin) is a form of vitamin A that is very concentrated. It can only be obtained by prescription. The oily liquid comes in a soft capsule. Brand names for this medicine are Amnesteem®, Absorica®, Claravis®, Myorisan® and Zenatane®. Isotretinoin is used to treat neuroblastoma, the most common type of cancer in children. This medicine is given along with other immunotherapy (cancer fighting) drugs during the active stage of illness. It may also be ordered to be taken during the maintenance phase of therapy. Usually isotretinoin is given after the child has received the medicine 131I- Metaiodobenzylguanidine (MIBG) and has had a Bone Marrow Transplant (BMT). Warnings If your child is allergic to retinoids, he should not take this medicine. When handling this drug, extreme care needs to be followed by women who are pregnant or breastfeeding. Isotretinoin can cause severe birth defects and can pass into breast milk. Someone else will need to give this medicine to your child. Because of the dangers of birth defects with isotretinoin, your child, your child’s doctor, and your pharmacy must register with the iPLEDGE™ program. To do this, go to www.ipledgeprogram.com. Failure to register means that your child will not get the medicine. When your child needs more medicine, the doctor will have to write a new prescription each time. How to give Isotretinoin can be given by mouth whole, buried in food whole, or dissolved and mixed with food. Always wear disposable gloves if there is a risk of touching the liquid inside the capsule.
    [Show full text]
  • Acitretin; Adapalene; Alitretinoin; Bexarotene; Isotretinoin
    8 February 2018 EMA/254364/2018 Pharmacovigilance Risk Assessment Committee (PRAC) Assessment report Referral under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data Retinoids containing medicinal products INN: Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin, Tazarotene Procedure number: EMEA/H/A-31/1446 Panretin EMEA/H/A-31/1446/C/000279/0037 Targretin EMEA/H/A-31/1446/C/000326/0043 Note: Assessment report as adopted by the PRAC and considered by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ......................................................................................... 2 1. Information on the procedure ................................................................. 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Clinical aspects .................................................................................................... 5 2.3. Data on efficacy ..................................................................................................
    [Show full text]
  • Aetna Formulary Exclusions Drug List
    Covered and non-covered drugs Drugs not covered – and their covered alternatives 2020 Advanced Control Plan – Aetna Formulary Exclusions Drug List 05.03.525.1B (7/20) Below is a list of medications that will not be covered without a Key prior authorization for medical necessity. If you continue using one of these drugs without prior approval, you may be required UPPERCASE Brand-name medicine to pay the full cost. Ask your doctor to choose one of the generic lowercase italics Generic medicine or brand formulary options listed below. Preferred Options For Excluded Medications1 Excluded drug name(s) Preferred option(s) ABILIFY aripiprazole, clozapine, olanzapine, quetiapine, quetiapine ext-rel, risperidone, ziprasidone, VRAYLAR ABSORICA isotretinoin ACANYA adapalene, benzoyl peroxide, clindamycin gel (except NDC^ 68682046275), clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, EPIDUO, ONEXTON, TAZORAC ACIPHEX, esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT ACIPHEX SPRINKLE ACTICLATE doxycycline hyclate capsule, doxycycline hyclate tablet (except doxycycline hyclate tablet 50 mg [NDC^ 72143021160 only], 75 mg, 150 mg), minocycline, tetracycline ACTOS pioglitazone ACUVAIL bromfenac, diclofenac, ketorolac, PROLENSA acyclovir cream acyclovir (except acyclovir cream), valacyclovir ADCIRCA sildenafil, tadalafil ADZENYS XR-ODT amphetamine-dextroamphetamine mixed salts ext-rel†, dexmethylphenidate ext-rel, dextroamphetamine ext-rel, methylphenidate ext-rel†, MYDAYIS,
    [Show full text]
  • NG198 Evidence Review F1
    FINAL Management options for people with moderate to severe acne vulgaris - network meta-analyses Research recommendations for review question: For people with moderate to severe acne vulgaris what are the most effective treatment options? Research question - reduced dose oral isotretinoin What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris? Why this is important Oral isotretinoin is prescribed by consultant dermatologist-led team for severe forms of acne resistant to adequate courses of standard therapy with systemic antibacterials and topical therapy. The daily dose typically ranges between 0.5mg to 1mg/kg, however dosage adjustments may be required for people with severe intolerances or whom are at higher risk of developing serious adverse effects. There is limited high-quality data on the efficacy and optimum treatment duration of reduced (less than 0.5mg/kg) daily dose isotretinoin in acne. Furthermore, there have been reports of the successful use of reduced daily dose isotretinoin, including weekly (mini) or bi-weekly (micro) dosage regime as maintenance therapy in people with recurrent relapse despite adequate response to multiple courses of isotretinoin. The evidence for reduced dose isotretinoin as maintenance therapy have been limited to case series and small cohort studies. Further research will help to establish if • reduced daily dose of oral isotretinoin is effective in the treatment of acne vulgaris • reduced dose isotretinoin regime is effective as maintenance therapy; and • the optimum duration of treatment. Table 26: Research recommendation rationale Research question What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris? Why is this needed Importance to ‘patients’ or the The daily dose of isotretinoin prescribed usually ranges between population 0.5mg – 1mg/kg.
    [Show full text]
  • Acitretin; Adapalene; Alitretinoin; Bexarotene; Isotretinoin
    21 June 2018 EMA/261767/2018 Updated measures for pregnancy prevention during retinoid use Warning on possible risk of neuropsychiatric disorders also to be included for oral retinoids On 22 March 2018, the European Medicines Agency (EMA) completed its review of retinoid medicines, and confirmed that an update of measures for pregnancy prevention is needed. In addition, a warning on the possibility that neuropsychiatric disorders (such as depression, anxiety and mood changes) may occur will be included in the prescribing information for oral retinoids (those taken by mouth). Retinoids include the active substances acitretin, adapalene, alitretinoin, bexarotene, isotretinoin, tazarotene and tretinoin. They are taken by mouth or applied as creams or gels to treat several conditions mainly affecting the skin, including severe acne and psoriasis. Some retinoids are also used to treat certain forms of cancer. The review confirmed that oral retinoids can harm the unborn child and must not be used during pregnancy. In addition, the oral retinoids acitretin, alitretinoin and isotretinoin, which are used to treat conditions mainly affecting the skin, must be used in accordance with the conditions of a new pregnancy prevention programme by women able to have children. Topical retinoids (those applied to the skin) must also not be used during pregnancy, and by women planning to have a baby. More information is available below. Regarding the risk of neuropsychiatric disorders, the limitations of the available data did not allow to clearly establish whether this risk was due to the use of retinoids. However, considering that patients with severe skin conditions may be more vulnerable to neuropsychiatric disorders due to the nature of the disease, the prescribing information for oral retinoids will be updated to include a warning about this possible risk.
    [Show full text]
  • Oral Alitretinoin in Congenital Ichthyosis: a Pilot Study Shows Variable Effects and a Risk of Central Hypothyroidism
    Included in the theme issue: 256 Letters to the Editor ACNE, RETINOIDS AND LYMPHOMAS Acta Derm Venereol 2012; 92: 256–257 Oral Alitretinoin in Congenital Ichthyosis: A Pilot Study Shows Variable Effects and a Risk of Central Hypothyroidism Agneta Gånemo1, Mette Sommerlund2 and Anders Vahlquist3* 1Department of Dermatology, Institute of Clinical Research in Malmö, Lund University, Skåne University Hospital, Malmö, Sweden, 2Department of Dermatology and Venereology, Aarhus University Hospital, Aarhus, Denmark, and 3Department of Medical Sciences (Dermatology), Uppsala University, Uppsala, Sweden. E-mail: [email protected] Accepted October 20, 2011. Congenital ichthyosis is a large group of hereditary skin planned treatment period of 3 months. Clinical and laboratory disorders with different aetiologies, all of which are pre- evaluations were performed before the start of therapy and at monthly intervals, and consisted of physical examination, pho- sent at birth (1). The patients have dry, widespread scaling tography, interviewing the patients about effects and side-effects and thickened skin (2). At present there is no cure for of therapy, and blood sampling for analysis of haematological ichthyosis and therapy is mostly symptomatic. Life-long parameters, liver enzymes, creatinine, cholesterol, triglycerides, treatment with emollients is essential, and some patients thyroxin (T4) and tyroid-stimulating hormone (TSH) levels. also use systemic therapy with retinoids, especially aci- tretin (3). The most serious adverse effect of retinoids is RESULTS teratogenicity, which is a special concern for acitretin as it is excreted from the body slowly (3). All 4 patients completed the 3-month long trial, and two Alitretinoin (9-cis retinoic acid) is a fairly new oral of them (nos 1 and 3) wished to continue alitretinoin retinoid with more rapid clearance than acitretin.
    [Show full text]
  • Spironolactone for Adult Female Acne
    ® PPracticalEDIATRIC DERMATOLOGY Pearls From the Cutis Board Spironolactone for Adult Female Acne Many cases of acne are hormonal in nature, meaning that they occur in adolescent girls and women and are aggravated by hormonal fluctuations such as those that occur during the menstrual cycle or in the setting of underlying hormonal imbalances as seen in polycystic ovary syndrome. For these patients, antihormonal therapy such as spironolactone is a valid and efficacious option. Herein, initiation and utilization of this medication is reviewed. Adam J. Friedman, MD copy What should you do during the first Evaluation of these women with acne for the visit for a patient you may start possibility of hormonal imbalance may be necessary, on spironolactone? with the 2 most common causes of hyperandrogen- Some women will come in asking about spironolac- ismnot being polycystic ovary syndrome and congeni- tone for acne, so it is important to identify potential tal adrenal hyperplasia. The presence of alopecia, candidates for antihormonal therapy: hirsutism, acanthosis nigricans, or other signs of • Women with acne flares that cycle androgen excess, in combination with dysmenor- with menstruation Dorhea or amenorrhea, may be an indication that the • Women with adult-onset acne or persistent- patient has an underlying medical condition that recurrent acne past teenaged years, even needs to be addressed. Blood tests including testos- in the absence of clinical or laboratory signs terone, dehydroepiandrosterone, follicle-stimulating of hyperandrogenism hormone, and luteinizing hormone would be appro- • Women on oral contraceptives (OCs) who priate screening tests and should be performed dur- exhibit moderate to severe acne, especially ing the menstrual period or week prior; the patient with a hormonal patternCUTIS clinically should not be on an OC or have been on one within • Women not responding to conventional ther- the last 6 weeks of testing.
    [Show full text]
  • [Docket No. FDA-2020-N-1058] Keith Komar
    This document is scheduled to be published in the Federal Register on 10/20/2020 and available online at federalregister.gov/d/2020-23135, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2020-N-1058] Keith Komar: Final Debarment Order AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Keith Komar for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Komar was convicted of one felony count under Federal law for mail fraud. The factual basis supporting Mr. Komar’s conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Komar was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of 30 days after receipt of the notice (July 22, 2020), Mr. Komar had not responded. Mr. Komar’s failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter. DATES: This order is applicable [INSERT DATE OF PUBLICATION IN THE FEDERAL REGISTER]. ADDRESSES: Submit applications for termination of debarment to the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: Jaime Espinosa, Division of Enforcement, Office of Strategic Planning and Operational Policy, Office of Regulatory Affairs, Food and Drug Administration, 12420 Parklawn Dr., Rockville, MD 20857, 240-402-8743, or at [email protected].
    [Show full text]